New England Asset Management Inc. Sells 900 Shares of Bristol-Myers Squibb Company (BMY)

New England Asset Management Inc. trimmed its position in Bristol-Myers Squibb Company (NYSE:BMY) by 2.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,000 shares of the biopharmaceutical company’s stock after selling 900 shares during the period. New England Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $2,340,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Tradewinds Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 500 shares during the period. Proficio Capital Partners LLC lifted its holdings in shares of Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares during the period. American National Bank lifted its holdings in shares of Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares during the period. Blue Chip Partners Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the period. Finally, Heritage Trust Co purchased a new position in shares of Bristol-Myers Squibb during the 1st quarter worth about $123,000. Institutional investors own 69.82% of the company’s stock.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $63.53 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The stock has a market cap of $102,146.62, a P/E ratio of 21.08, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the business earned $0.77 EPS. The firm’s revenue was up 6.7% compared to the same quarter last year. equities research analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a $0.40 dividend. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.52%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 61.42%.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is owned by company insiders.

Several brokerages have recently weighed in on BMY. Vetr lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective on the stock. in a report on Tuesday, August 22nd. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. Finally, Cowen set a $65.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $64.93.

WARNING: This article was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://sportsperspectives.com/2017/12/12/new-england-asset-management-inc-sells-900-shares-of-bristol-myers-squibb-company-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply